Prokaryotic Expression and Neutralization Activity Detection of SARS-CoV-2 Neutralizing Nanobody

doi:10.19586/j.2095-2341.2022.0042

Current Biotechnology ›› 2022, Vol. 12 ›› Issue (5): 754-759.DOI: 10.19586/j.2095-2341.2022.0042

• Articles • Previous Articles Next Articles

Prokaryotic Expression and Neutralization Activity Detection of SARS-CoV-2 Neutralizing Nanobody

Haining WANG¹^,²^,³(), Xingjian LIU³, Xintao GAO³, Yinv LI³, Xingjia SHEN¹^,², Zhifang ZHANG³, Yongzhu YI¹^,²()

^1.Jiangsu Key Laboratory of Sericulture Biology and Biotechnology，College of Biotechnology，Jiangsu University of Science and Technology，Jiangsu Zhenjiang 212100，China
^2.Key Laboratory of Sericulture Genetic Improvement，Ministry of Agriculture and Rural Affairs，Institute of Sericulture，Chinese Academy of Agricultural Sciences，Jiangsu Zhenjiang 212100，China
^3.Biotechnology Research Institute，Chinese Academy of Agricultural Sciences，Beijing 100081，China

Received:2022-03-21 Accepted:2022-07-07 Online:2022-09-25 Published:2022-09-30
Contact: Yongzhu YI

SARS-CoV-2中和性纳米抗体的原核表达及中和活性检测

王海宁¹^,²^,³(), 刘兴健³, 高新桃³, 李轶女³, 沈兴家¹^,², 张志芳³, 易咏竹¹^,²()

^1.江苏科技大学生物技术学院，江苏省蚕桑生物学与生物技术重点实验室，江苏镇江 212100
^2.中国农业科学院蚕业研究所，农业农村部蚕桑遗传改良重点实验室，江苏镇江 212100
^3.中国农业科学院生物技术研究所，北京 100081

通讯作者: 易咏竹
作者简介:王海宁 E-mail: 1585676756@qq.com；
基金资助:
宁夏回族自治区重点研发计划(2020BFG02017);国家自然科学基金项目(32002236)

Abstract

Abstract:

Nanobody， as the smallest unit known to bind to target antigen， has a good application prospect in biomedicine and clinical research. According to the optimization of Escherichia coli codon preference， the gene of nanobody H11-D4 neutralizing severe acute respiratory syndrome-coronavirus 2（SARS-CoV-2） was synthesized and cloned into pET28a expression vector and transformed into E. coli competent cell Rosetta（DE3）for induced expression. The expression of H11-D4 was identified by nickel column purification， mass spectrometry and Western blot， its activity was verified by neutralization test. The experimental results showed that the nanobody H11-D4 had been successfully expressed in E. coli. The optimal induction conditions were determined to be an induction temperature of 37 ℃，an induction time of 5 h，and IPTG final concentration of 1.0 mmol·L^-1. The molecular weight was about 17.9 kD， which was consistent with the predicted value. After nickel column purification， the yield of H11-D4 protein was 25.16 mg·L^-1. After dialysis renaturation， endotoxin was removed quickly and effectively by Triton X-114. The neutralization test successfully verified that the neutralization activity（IC₅₀）of H11-D4 was 171.1 nmol·L^-1. The results obtained in this study could provide basic data support for the prokaryotic expression of nanobody and prevention and treatment of corona virus disease 2019（COVID-19）.

Key words: nanobody, Escherichia coli, SARS-CoV-2, neutralization test

摘要：

纳米抗体（nanobody，Nb）作为目前已知的能与目标抗原结合的最小单位抗体，在生物医药、临床研究等方面具有良好的应用前景。根据大肠杆菌密码子偏好性优化合成严重急性呼吸综合征冠状病毒2（severe acute respiratory syndrome-coronavirus 2，SARS-CoV-2）中和性纳米抗体H11-D4基因，将其克隆到pET28a表达载体上后，转化至大肠杆菌感受态细胞Rosetta（DE3）进行诱导表达，通过镍柱纯化、质谱分析、Western Blot鉴定H11-D4的表达情况并使用中和试验验证其中和活性。研究结果显示，纳米抗体H11-D4可成功在大肠杆菌中表达，最佳诱导条件为IPTG终浓度1.0 mmol·L^-1，37 ℃诱导5 h。H11-D4抗体的分子量大小约为17.9 kD，与预测值相符。经镍柱纯化后，产量为25.16 mg·L^-1。透析复性后利用TritonX-114快速有效地去除了内毒素，中和试验成功验证了H11-D4的中和活性（IC₅₀）为171.1 nmol·L^-1，研究结果可为纳米抗体的原核表达和新型冠状病毒肺炎（corona virus disease 2019，COVID-19）的预防及治疗提供基础数据支撑。

关键词: 纳米抗体, 大肠杆菌, 新冠病毒, 中和试验

CLC Number:

R392-33

Haining WANG, Xingjian LIU, Xintao GAO, Yinv LI, Xingjia SHEN, Zhifang ZHANG, Yongzhu YI. Prokaryotic Expression and Neutralization Activity Detection of SARS-CoV-2 Neutralizing Nanobody[J]. Current Biotechnology, 2022, 12(5): 754-759.

王海宁, 刘兴健, 高新桃, 李轶女, 沈兴家, 张志芳, 易咏竹. SARS-CoV-2中和性纳米抗体的原核表达及中和活性检测[J]. 生物技术进展, 2022, 12(5): 754-759.

Figures/Tables 7

Fig. 1 Identification of recombinant plasmid pET28a-H11-D4 by double enzyme digestion

Fig. 2 SDS-PAGE analysis of recombinant protein H11-D4

Fig. 3 SDS-PAGE analysis and concentration determination after H11-D4 purification

Fig. 4 Western Blot analysis of H11-D4

Fig. 5 Expression of ACE2-GFP in 293T cells

Fig. 6 Determination of pseudovirus infectivity

Fig. 7 Neutralization activity curve of H11-D4 to pseudovirus

References 22

1	WALLS A C, PARK Y J, TORTORICI M A, et al.. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein[J]. Cell, 2020, 181(2): 281-292.
2	CRUZ-TERAN C, TIRUTHANI K, MCSWEENEY M, et al.. Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy[J]. Adv. Drug Deliv. Rev., 2021, 169: 100-117.
3	WU Y, LI C, XIA S, et al.. Identification of human single-domain antibodies against SARS-CoV-2[J]. Cell Host Microbe., 2020, 27(6): 891-898.
4	TIAN X, LI C, HUANG A, et al.. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody[J]. Emerg. Microbes. Infec., 2020, 9(1): 382-385.
5	杨高松,马东杰.呼吸道传染病治疗中抗体药物的研发进展[J]. 生物技术进展, 2020, 10(5): 441-447.
6	WU Y, JIANG S, YING T. Single-domain antibodies aAs therapeutics against human viral diseases[J/OL]. Front. Immunol., 2017, 8(1802)[2017-12-13]. .
7	BUSS N A, HENDERSON S J, MCFARLANE M, et al.. Monoclonal antibody therapeutics: history and future[J]. Curr. Opin. Pharmacol., 2012(12): 615-622.
8	LAWSON A D. Antibody-enabled small-molecule drug discovery[J]. Nat. Rev. Drug Discov., 2012, 11(7): 519-525.
9	YUAN M, WU N C, ZHU X, et al.. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV[J]. Science, 2020, 368(6491): 630-633.
10	STEELAND S, VANDENBROUCKE R E, LIBERT C. Nanobodies as therapeutics: big opportunities for small antibodies[J]. Drug Discov. Today, 2016, 21(7): 1076-1113.
11	BOULENOUAR H, AMAR Y, BOUCHOUTROUCH N, et al.. Nanobodies and their medical applications[J/OL]. Genet. Mol. Res., 2020, 19:gmr184521[2020-05-26]. .
12	HUO J, LE BAS A, RUZA R R, et al.. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2[J]. Nat. Struct. Mol. Biol., 2020, 27(9): 846-854.
13	SAMARANAYAKE H, WIRTH T, SCHENKWEIN D, et al.. Challenges in monoclonal antibody-based therapies[J]. Ann. Med., 2009, 41: 322-331.
14	BANNAS P, HAMBACH J, KOCH-NOLTE F. Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics[J/OL]. Front. Immunol., 2017, 8: 1603[2017-11-22]. .
15	HASSANZADEH-GHASSABEH G, DEVOOGDT N, DE AUW P, et al.. Nanobodies and their potential applications[J]. Nanomedicine, 2013, 8(6): 1013-1026.
16	VAN HEEKE G, ALLOSERY K, De BRABANDERE V, et al.. Nanobodies^® as inhaled biotherapeutics for lung diseases[J]. Pharmacol. Ther., 2017, 169: 47-56.
17	LIU Y, HUANG H. Expression of single-domain antibody in different systems[J]. Appl. Microbiol. Biotechnol., 2018, 102(2): 539-551.
18	VEGGIANI G, DE MARCO A. Improved quantitative and qualitative production of single-domain intrabodies mediated by the co-expression of Erv1p sulfhydryl oxidase[J]. Protein Expr. Purif., 2011, 79(1): 111-114.
19	XUE X, FAN X, QU Q, et al.. Bioscreening and expression of a camel anti-CTGF VHH nanobody and its renaturation by a novel dialysis-dilution method[J/OL]. AMB Express, 2016, 6(1): 72[2016-09-13]. .
20	张云鹏,温彤,姜伟.大肠杆菌和酵母表达系统的研究进展[J]. 生物技术进展, 2014, 4(6): 389-393.
21	KUO M M, NGUYEN P H, JEON Y H, et al.. MB109 as bioactive human bone morphogenetic protein-9 refolded and purified from E.coli inclusion bodies[J/OL]. Microb. Cell Fact. 2014, 13(1): 29[2014-01-24]. .
22	LOPES A M, SANTOS-EBINUMA V C, NOVAES L C, et al.. LPS-protein aggregation influences protein partitioning in aqueous two-phase micellar systems[J]. Appl. Microbiol. Biotechnol., 2013, 97(14): 6201-6209.

[1]	Yanhua LIU, Rui GUO, Yanyi LI, Jinli CHEN. Progress on the Development of Vaccines Related to Chronic Respiratory Diseases [J]. Current Biotechnology, 2025, 15(3): 396-403.
[2]	Shuanghui ZHOU. Microbial Contamination and Antibiotic Resistance Characteristics in Raw Milk from Pastures in Northern Fujian Province [J]. Current Biotechnology, 2025, 15(1): 127-134.
[3]	Xi KANG, Ziyu LIN, Yishu YANG, Jintao LI, Minglian WANG. Variation Analysis of SARS-CoV-2 Omicron RdRp and Construction of its Active Reaction System [J]. Current Biotechnology, 2024, 14(6): 1042-1054.
[4]	Kai DU, Zhuoling ZHANG, Li GAO, Haihua HE, Tinghua LI, Wei RAO. Application of Anti-idiotype Antibodies in Haptens Immunoassay [J]. Current Biotechnology, 2023, 13(5): 690-697.
[5]	Xiaoyan PENG, Panpan LU, Zuquan HU. Prokaryotic Expression of the RBD Protein of SARS-CoV-2 and its Polyclonal Antibodies Preparation [J]. Current Biotechnology, 2023, 13(1): 102-106.
[6]	Dan LI, Haozhi SONG, Weisong GAO, Xingjian LIU, Zhifang ZHANG, Yinyu LI. Prokaryotic Expression and Immunogenicity Detection of the H Protein of Peste des Petits Ruminants Virus [J]. Current Biotechnology, 2021, 11(6): 770-776.
[7]	HU Sihong, YOU Guoye. Application Prospects of Digital PCR in Detection of SARS-CoV-2 [J]. Curr. Biotech., 2020, 10(6): 674-679.

Prokaryotic Expression and Neutralization Activity Detection of SARS-CoV-2 Neutralizing Nanobody

SARS-CoV-2中和性纳米抗体的原核表达及中和活性检测

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 7

References 22

Related Articles 7

Recommended Articles

Metrics

Comments